Rezolute, Inc. (RZLT) stock
RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
$4.01+0.43 (+12.15%)
Close on Nov 17, 2026Market cap $388.34MP/E –Yield –
Rezolute r&d expenses
Research and development expenses are spending on new products and technology.
Rezolute's R&D Expenses for the twelve months ending Sep 30, 2026 was $53.46M, down 13.7% year over year. For fiscal 2026 it was $53.80M, down 12.6% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $61.53M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $53.80M | -12.6% |
| FY2025 | Jun 30, 2025 | $61.53M | +10.4% |
| FY2024 | Jun 30, 2024 | $55.74M | +27.2% |
| FY2023 | Jun 30, 2023 | $43.81M | +34.9% |
| FY2022 | Jun 30, 2022 | $32.49M | +116.8% |
| FY2021 | Jun 30, 2021 | $14.99M | +3.7% |
| FY2020 | Jun 30, 2020 | $14.45M | -24.3% |
| FY2019 | Jun 30, 2019 | $19.08M | +10.4% |
| FY2018 | Jun 30, 2018 | $17.28M | +42.9% |
| FY2017 | Jun 30, 2017 | $12.09M | +28.0% |
| FY2016 | Jun 30, 2016 | $9.45M | +101.0% |
| FY2015 | Jun 30, 2015 | $4.70M | +13599.4% |
| FY2014 | Jun 30, 2014 | $34.32K | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $12.81M | -2.6% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $14.89M | -28.6% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $11.41M | -25.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $14.35M | +13.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $13.15M | +3.1% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $20.86M | +9.3% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $15.28M | +23.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $12.63M | +4.9% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $12.75M | +4.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $19.09M | +74.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $12.40M | -12.9% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $12.04M | +10.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $12.21M | +58.5% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $10.93M | +27.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $14.23M | +63.8% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $10.95M | +15.8% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $7.70M | +33.4% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $8.57M | +95.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $8.69M | +131.1% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $9.45M | +110.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $5.77M | +146.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $4.39M | +79.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $3.76M | +0.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $4.50M | -10.8% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $2.34M | -27.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $2.45M | -65.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $3.73M | +49.5% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $5.04M | +47.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $3.23M | -25.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $7.06M | +128.2% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $2.50M | -27.4% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $3.41M | +11.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $4.31M | +73.4% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $3.09M | +16.9% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $3.44M | +48.9% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $3.08M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $2.49M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $2.65M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $2.31M | – |
See a number that looks wrong?